St. Paul Global Week brings pilgrims to Tarsus, Türkiye, from 28 to 30 June 2027 for a three-day gathering in the Apostle ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
If the acquisition is finalised, Tarsus will join the race to market in rare eye condition, Stargardt disease. Credit: 24K-Production / Shutterstock.com. Tarsus Pharmaceuticals has forged a takeover ...
Transaction structure includes $270 million cash, $180 million equity at $61.38/share, up to $350 million milestones, and low single-digit tiered descending royalties on net sales. Mechanistic ...
Bobak Azamian (Co-Founder, President, CEO & Chairman) said, "Today is an important day for Tarsus. We're reporting another exceptional quarter for XDEMVY and announcing the acquisition of Alkeus ...
Tarsus has agreed to buy Alkeus in an $800 million deal that will give it rights to a drug for rare eye disorder Stargardt disease that has "blockbuster potential." The takeover revolves around Alkeus ...
Alkeus Pharmaceuticals, an unorthodox biotechnology startup advancing a new medicine for a genetic eye condition, is selling itself in a deal worth up to $800 million. The purchase announced Thursday ...
Tarsus Pharmaceuticals, Inc (TARS), a biopharmaceutical company focused on eye care, has entered into a definitive agreement to acquire Alkeus Pharmaceuticals, Inc., a retinal disease-focused ...
To broaden its ophthalmology portfolio, Tarsus Pharmaceuticals is dishing out $450 million upfront to acquire Phase 3 biotech Alkeus Pharmaceuticals, the companies said Thursday ...
Tarsus Pharmaceuticals (TARS) agreed to acquire privately held Alkeus Pharmaceuticals, gaining gildeuretinol (ALK-001), an investigational once-daily oral therapy for Stargardt disease, a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results